加载中
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
收盘时
US$29.42
−US$0.41 · -1.37%
盘后
US$29.29
−US$0.13 · -0.44%
10月6日 19:38 ET
盘中时间采用ET。市场数据可能有所延迟。
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
日内区间
当前US$29.42
52周区间
当前US$29.42
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
33
偏贵
情绪
53
多空交织
风险
50
风险偏高
动量
73
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
日内区间
当前US$29.42
52周区间
当前US$29.42
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | — | −84.6万 USD | — |
| 毛利 | — | — | — | 84.6万 USD | — |
| 研究与开发 | 2.15亿 USD | 1.26亿 USD | 7822.5万 USD | 6983.9万 USD | 2248.4万 USD |
| 销售、一般及管理费用 | 1亿 USD | 4099.8万 USD | 2378.7万 USD | 2191万 USD | 1191.8万 USD |
| 营业费用 | 3.15亿 USD | 1.67亿 USD | 1.02亿 USD | 9174.9万 USD | 3440.2万 USD |
| 利息收入 | 2447.9万 USD | 2071.4万 USD | 797.9万 USD | 175万 USD | 1.5万 USD |
| 利息支出 | 753.1万 USD | 762.6万 USD | 378.6万 USD | 99.2万 USD | 2万 USD |
| 折旧和摊销 | 46.8万 USD | 10.5万 USD | 2.1万 USD | −84.6万 USD | 17.6万 USD |
| 营业利润 | −3.15亿 USD | −1.67亿 USD | −1.02亿 USD | −9090.3万 USD | −3440.2万 USD |
| 净利润 | −3亿 USD | −1.52亿 USD | −9599万 USD | −8905.6万 USD | −3260.9万 USD |
公司数据更新于 2026年10月7日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$86.75
上涨空间 194.87%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6610.85万0.00%2.3万亿 USD0.03%US$382.54+0.51%
State Street SPDR S&P Biotech ETFXBI5423.22万0.54%100.95亿 USD0.35%US$150.9-3.39%
iShares Russell 2000 ETFIWM4966.51万0.06%790.26亿 USD0.19%US$281.34-0.72%
Vanguard Extended Market ETFVXF2615.15万0.03%954亿 USD0.05%US$237.2+0.02%
iShares Russell 2000 Growth ETFIWO1785.51万0.12%142.94亿 USD0.24%US$360.53-0.90%
iShares Biotechnology ETFIBB1336.3万0.13%105.49亿 USD0.44%US$203.1-2.34%
Vanguard Russell 2000 ETFVTWO1251.56万0.07%180亿 USD0.06%US$113.64-0.69%
Schwab U.S. Small-Cap ETFSCHA974.5万0.04%220.83亿 USD0.03%US$33.10-0.42%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
